Table 1 Patient characteristics

From: Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

  Lenalidomide cohort All
  5 mg, n=3 10 mg, n=3 15 mg, n=3 20 mg, n=6 25 mg, n=12 n=27 %
Age
 Median 44 59 56 58.5 58.5 58  
 Range 43–69 52–67 24–62 57–77 47–67 24–77  
 >60 years 1 1 1 2 6 11  
Sex
 Female 2 1 3 1 4 11 41
 Male 1 2 0 5 8 16 59
Performance status
 0 1 3 1 2 8 15 56
 1 2 0 2 4 4 12 44
Lymphoma type
 Follicular 3 2 1 4 8 18 67
 Mantle cell 0 0 0 1 2 3 11
 DLBCL 0 0 1 1 2 4 15
 Indolent unclassified 0 1 1 0 0 2 7
Stage
 I 0 0 1 0 0 1 4
 II 0 0 0 0 1 1 4
 III 0 0 0 2 2 4 15
 IV 3 3 2 4 9 21 78
LDH
 Normal 0 2 1 3 7 13 48
 >Normal 3 1 2 3 5 14 52
Extranodal sites
 0–1 0 1 1 2 6 10 37
 >1 3 2 2 4 6 17 63
Bone marrow
 Not involved 0 2 1 4 4 11 41
 Involved 3 1 2 2 7 15 56
 Not done 0 0 0 0 1 1 4
  1. Abbreviation: DLBCL, diffuse large B-cell lymphoma.
Back to article page